Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + potassium clavulanate + lactic acid bacillus
- Development stage
- Unknown
- Lead developer
- Vintek Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amoxicillin + potassium clavulanate + lactic acid bacillus is a combination pharmaceutical product containing a broad-spectrum beta-lactam antibiotic, a beta-lactamase inhibitor, and a probiotic. **Amoxicillin** acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. **Potassium clavulanate** is a suicide inhibitor of beta-lactamase enzymes, which prevents the enzymatic degradation of amoxicillin and extends its activity against resistant bacterial strains. **Lactic acid bacillus** (specifically *Lactobacillus acidophilus*) is included as a probiotic to restore healthy intestinal microflora that are often disrupted during antibiotic therapy, thereby reducing the risk of antibiotic-associated diarrhea. This combination is primarily marketed in India for the treatment of various bacterial infections, including pneumonia, otitis media, sinusitis, and urinary tract infections.
- Brand names
- Clavson-625 LBClavson625 LBClavson 625 LBVIMOXY CV-625-LB
- Other names
- Amoxycillin + Potassium Clavulanate + Lactic Acid Bacillus
02
Targets
β-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on amoxicillin + potassium clavulanate + lactic acid bacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + potassium clavulanate + lactic acid bacillus.